Health Secretary cites safety concerns and public opposition to mRNA technology used in Covid and flu vaccines.

The U.S. Department of Health and Human Services (HHS) has announced the cancellation of $500 million in federal funding for mRNA vaccine research and development. The funding had been allocated to projects aimed at countering respiratory viruses such as Covid-19 and seasonal influenza.

Health Secretary Robert F. Kennedy Jr., who took office earlier this year, stated that the decision was made due to growing concerns over the safety and efficacy of mRNA-based vaccines when used against these types of viruses.

“After a thorough review, we have determined that mRNA technology poses more risks than benefits for these respiratory viruses,” Kennedy said during a press briefing. “We must prioritize public trust and safety in all of our health initiatives.”

The funding cut affects several public-private partnerships and research programs, many of which were initiated in response to the Covid-19 pandemic and expanded under the government’s pandemic preparedness strategy.

Controversial Legacy of mRNA Tech
mRNA vaccine technology rose to prominence during the Covid-19 pandemic, praised for its rapid development timeline and adaptability. However, it also faced intense scrutiny over its long-term safety, side effects, and the role of vaccine mandates, which Kennedy referred to as “coercive” and “divisive.”

“The pandemic response fractured public trust,” Kennedy said. “Moving forward, our health strategy must be rooted in transparency, choice, and proven science.”

Public Reaction Mixed
The move has sparked mixed reactions across the political and scientific spectrum. Critics argue that mRNA research still holds promise, especially for developing vaccines against cancer and other diseases, while supporters of the decision praise the administration for reevaluating government spending priorities and responding to public sentiment.